Denmark · Delayed Price · Currency is DKK Gubra Company Description
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally.
It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology.
It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition.
The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus’ FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
| Country | Denmark |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Markus Rohrwild |
Contact Details
Address: Hørsholm Kongevej 11B Horsholm, 2970 Denmark | |
| Phone | 45 31 52 26 50 |
| Website | gubra.dk |
Stock Details
| Ticker Symbol | GUBRA |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0062266474 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Markus Rohrwild Ph.D. | Chief Executive Officer |
| Jacob Jelsing | Co-Founder and Director |
| Dr. Niels Vrang M.D., Ph.D. | Co-founder and Director |
| Kristian Borbos | Chief Financial Officer |
| Line Holten Reimer | Chief Investment Officer |
| Grigo Gaurav | Chief Technology Officer |
| Louise Schjellerup Dalboge | Chief Science Officer |
| Adam Lange | Head of Investor Relations |
| Lena Moran-Adams L.L.B. | Group General Counsel |
| Trine Nygaard Hamann | Head of Gubra CRO |